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Abstract: Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome
and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive
effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown.
This randomized, double-blind, placebo-controlled study explored the effect of vitamin D
supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight,
body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model
assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone,
sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT),
hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor
of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women
with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months.
All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in
vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4 nmol/L,
FU: 90.4 ± 19.5 nmol/L vs. placebo, baseline: 30.9 ± 11.1 nmol/L, FU: 47.6 ± 20.5 nmol/L, p < 0.001).
Between groups comparisons (% baseline change) revealed significant differences in ALT (p = 0.042)
and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051).
No further between group differences were seen in other cardiovascular risk factor, liver markers,
or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers
and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.
Keywords: polycystic ovary syndrome; vitamin D; liver markers; cardiovascular risk factors;
hormones
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1. Introduction
Polycystic ovary syndrome (PCOS), a common endocrine disorder, occurs in more than 10%
of women of reproductive age and is associated with increased prevalence of cardiovascular risk
factors (i.e., insulin resistance, hypertension, dyslipidemia), metabolic syndrome, and cardiovascular
diseases [1,2]. As a hepatic manifestation of the metabolic syndrome, several studies suggest
that women with PCOS are also at increased risk of developing non-alcoholic fatty liver disease
(NAFLD) [3,4], which encompasses a spectrum of diseases progressing from simple steatosis to
non-alcoholic steatohepatitis (NASH), and ultimately, cirrhosis [5]. In the general population,
NAFLD appears to significantly exacerbate metabolic outcomes, and it is considered an independent
risk factor for cardiovascular diseases [6,7]. Women with PCOS, and in particular those with
insulin resistance, have the potential to develop a more severe and rapidly progressive liver
disease at a young age, therefore, the early recognition of NAFLD and subsequent monitoring
and management (especially given that NAFLD can be potentially reversed) in this population are
considered of great clinical importance [5].
A recent meta-analysis demonstrated that vitamin D deficiency is common among women with
PCOS, with 67–85% having serum concentrations of 25-hydroxyvitamin D (25OHD) <20 ng/mL
(or 50 nmol/L) [8]. Low vitamin D correlates with obesity and it is associated with increased
insulin resistance, testosterone, and dehydroepiandrosterone sulphate (DHEAS) levels [9]. Studies on
vitamin D supplementation in PCOS have yielded mixed results, with some of them suggesting
beneficial effects on glucose metabolism and insulin resistance [10], especially when vitamin D
is given continuously at lower (<4000 IU/day) doses as suggested in a recent meta-analysis [11],
and improvements in menstrual frequency [12,13] and hyperandrogenism [13–15], whereas others
demonstrate no significant improvements [16–20]. Emerging evidence has associated NAFLD with
vitamin D deficiency, and in epidemiological studies, both conditions share multiple cardiovascular risk
factors [21,22]. Some vitamin D supplementation trials have shown positive effects on hepatic steatosis,
liver-related biochemical markers, or both in patients with NAFLD [23–25]; however, its effects in
women with PCOS have not been previously explored.
Although liver biopsy is the gold standard for NAFLD diagnosis and staging, as well
for evaluating the efficacy of potential treatments, its use is limited by cost, sampling errors,
and procedure-related morbidity and mortality [5]. Consequently, there is consensus that non-invasive
markers should be the first choice to exclude significant fibrosis due to their good inter-laboratory
reproducibility, high reliability, and widespread availability [26]. The enhanced liver fibrosis (ELF)
test is one of the first commercially available serum multi-marker fibrosis tests [27]. It has been
validated in various patient groups in a large multicenter study and has been found to be as accurate
as liver biopsy at predicting liver disease-related outcomes [28–30].
The aim of this study was to explore and compare the effects of vitamin D supplementation vs.
placebo on cardiovascular risk factors, hormones, and markers of liver injury and fibrosis in vitamin D
overweight and obese vitamin D deficient women with PCOS.
2. Materials and Methods
This double-blind, randomized, placebo-controlled study was performed in the Academic
Diabetes, Endocrinology, and Metabolism Unit, Hull University Teaching Hospitals NHS Trust,
Hull, United Kingdom. Fifty-four reproductive-aged women (18–45 years) diagnosed with PCOS
based on all three diagnostic criteria of the Rotterdam consensus were screened for vitamin D
deficiency [31]. Non-classical 21-hydroxylase deficiency, hyperprolactinemia, Cushing’s disease,
and androgen-secreting tumors were excluded by appropriate tests. The participants were considered
vitamin D-deficient, when their serum 25OHD levels were less than 20 ng/mL (<50 nmol/L).
We excluded PCOS women who: (1) had type 2 diabetes (all women had an oral glucose tolerance
test) or thyroid disorders, (2) were on medication that could interfere with calciotrophic hormones
for the preceding 6 months, (3) were planning to conceive or were using any oral or implantable
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contraceptives or any other treatments likely to affect ovarian function, insulin sensitivity, or lipids
for at least 3 months before entering the study, but a stable dose of metformin for 3 months was allowed,
(4) had nephrolithiasis or conditions resulting in hypercalcemia or hypercalciuria, and (5) had known
hypersensitivity to vitamin D or any of the excipients in the product and/or peanut or soya allergy.
None of the participants had NAFLD on ultrasound. All patients gave their written informed
consent before partaking. The study was given ethical approval by the NRES Committee Yorkshire
and the Humber - Leeds East. All methods were performed in accordance with the local Trust Research
and Development guidelines and regulations. This study was registered in the ClinicalTrials.gov
registry as NCT02513381.
Participants attended three visits (screening visit, baseline visit, 3 months follow-up).
In the screening visit, participants were screened against inclusion and exclusion criteria by medical
history, clinical examination, and routine blood tests. Forty eligible patients were randomly assigned
to take vitamin D 3200 IU (Swiss Caps AG, Cornu, Switzerland) or placebo (Swiss Caps AG,
Kirchberg, Switzerland) in capsule form once daily based on a computer-generated randomization
list by Essential Nutrition Ltd., U.K., and attended a baseline visit (baseline, initiation of intervention)
and a follow-up visit 3 months following vitamin D supplementation or placebo administration.
The supplementation arm was based on the National Osteoporosis Society, U.K. guidelines which
recommend treating patients who have serum 25OHD levels between 30–50 nmol/L and are
at increased risk of developing vitamin D deficiency in the future because of reduced exposure to
sunlight [32]. High-sensitivity C-reactive protein (hs-CRP), lipid profile, glucose levels, insulin levels,
and the homeostatic model assessment-insulin resistance (HOMA-IR) were assessed as the primary
outcome measures. As secondary outcomes, other cardiovascular risk factors (weight, body mass index
(BMI)), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG)),
and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal propeptide
of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the (ELF)
score) were evaluated. All participants were advised to maintain their usual dietary and lifestyle
habits during the study, including smoking, sunlight exposure, and physical activity that could affect
the levels of vitamin D and metabolic indices. The compliance with treatment was calculated by
counting the returned medications.
2.1. Study Measurements
During all visits, participants were weighed barefoot (Marsden Weighing Machine Group Ltd.,
Rotherham, UK). Blood pressure was measured using an automated device (NPB-3900; Nellcor Puritan
Bennett, Pleasanton, CA, USA); for this measurement, subjects were seated quietly for at least 5 min
and with the right arm supported at heart level. Three readings were taken, each at least 2 min apart,
and then the mean value of the readings was calculated. Following an overnight fast, venous blood
samples were collected and placed into fluoride oxalate and serum gel tubes. Samples were separated
by centrifugation at 2000× g for 15 min at 4 ◦C, and the aliquots were stored at −80 ◦C within 1 h
of collection. Overnight urine samples were collected and aliquots were stored at −80 ◦C until batch
analysis. Serum insulin was assayed using chemiluminescent immunoassay on the Beckman Coulter
UniCel DxI 800 analyzer (Beckman Coulter UK Ltd., High Wycombe, UK). Plasma glucose
was measured using a Beckman AU 5800 analyzer (Beckman-Coulter, High Wycombe, UK)
and according to the manufacturer’s recommended protocol. Insulin resistance was computed
as HOMA-IR = Glucose × Insulin/22.5 [33]. Serum vitamin D levels and testosterone were
quantified using isotope-dilution liquid chromatography tandem mass spectrometry (LC-MS/MS).
SHBG was measured using a chemiluminescent immunoassay on the UniCel DxI 800 analyzer
(Beckman-Coulter, High Wycombe, UK), applying the manufacturer’s recommended protocol.
The FAI was calculated as: (total testosterone/SHBG) x 100. Total cholesterol, triglycerides,
high-density lipoprotein cholesterol (HDL-C), ALT, and hs-CRP levels were measured enzymatically
using a Beckman AU 5800 analyzer (Beckman-Coulter, High Wycombe, UK). Low-density lipoprotein
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cholesterol (LDL-C) was calculated using the Friedewald equation. The ELF score provides a single
value using an algorithm combining serum measurements of three biomarkers including HA, TIMP-1,
and PIIINP. We used the ADVIA Centaur XP/XPT immunochemical analyzer (Siemens Healthcare
Diagnostics Inc., Erlangen, Germany) according to manufacturer’s instructions. The ELF score was
calculated directly by the instrument employing the following equation [30]:
ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln(CPIIINP) + 0.394 ln(CTIMP-1)
2.2. Statistical Analysis
Based on our previous work [34], this study was powered to detect differences in hs-CRP.
The minimum difference worth detecting/observed difference was 32.7%, with an effect size of 1.11;
therefore, for 90% power and a significance level of 5%, a sample size of 16 per group was calculated.
Adjusting for a possible 20% dropout rate meant a total of 40 patients need to be recruited
(nQuery, Statistical Solutions, Saugus, MA, USA). To negate the differences in the baseline values of
the two groups, data were expressed as percentage change from baseline for all variables. The effects
of treatment were evaluated by detecting differences in percentage changes between groups using
an independent t-test or the Mann-Whitney test. Data comparisons between baseline and follow-up
at 12 weeks within groups were carried out using the paired t-test (normally distributed data)
or the Wilcoxon signed rank test for non-normally distributed data. Data with normal distribution are
presented as means ± SD, while data following a skewed distribution are presented as medians with
interquartile range. All statistical analyses were performed using SPSS version 25.0 (IBM SPSS Statistics,
Chicago, IL, USA).
3. Results
Thirty-seven patients (vitamin D group, n = 18; placebo group, n = 19) completed the 3-month
study period. Two patients from the vitamin D group and one patient from placebo group dropped
out of the study (Figure 1). After their exclusion, compliance was 99% in both groups by counting
returned medication. None of the subjects developed any significant side effects over the course
of the study. The mean age group of patients was 28.6 ± 6.4 years (vitamin D 28.6 ± 5.5 vs.
placebo 29.1 ± 7.5 years). The baseline vitamin D levels, anthropometric, hormonal, and biochemical
parameters of the two groups are given in Table 1.
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The study started in July 2015 and the last patient’s last visit was in November 2016. Vitamin D
levels significantly increased at 3 months compared to baseline in both groups, with greater
increases shown in the women with PCOS who were randomized to the vitamin D supplementation
(vitamin D group, baseline: 25.6 ± 11.4 nmol/L, 3-month follow-up: 90.4 ± 19.5 nmol/L vs.
placebo group, baseline: 30.9 ± 11.1 nmol/L, 3-month follow-up: 47.6 ± 20.5 nmol/L, p < 0.001),
confirming adherence to supplementation.
There were no significant changes in weight, BMI, blood pressure, hs-CRP, lipid profile
(total cholesterol, LDL-C, HDL-C, TG), markers of insulin sensitivity (plasma glucose levels,
insulin levels, HOMA-IR), FAI, testosterone, or SHBG within vitamin D supplementation or
placebo group. Expressed as percentage change from baseline, there was a week effect, indicating
a greater reduction in HOMA-IR in the vitamin D group (p = 0.051), but no significance between group
differences were shown for any of these variables (Table 1).
Following 3 months of supplementation, the vitamin D group experienced significant reductions
in ALT levels (p = 0.042), HA levels (p = 0.019), and the cumulative ELF score (p = 0.022).
Within the placebo group, ALT levels increased at 3 months follow-up (p = 0.039), with no further
changes in any liver marker (Table 1). Between group comparisons revealed a difference in ALT
(% baseline change) (p = 0.001). Mean values of percentage change from baseline for HA, PIIINP,
and the ELF score were reduced in the vitamin D group and increased in the placebo group
after 3 months of supplementation; however, between groups comparison did not reach statistical
significance (Table 1).
Given that some participants in the vitamin D group (n = 3) and the placebo group ( n = 8) were on
metformin, which may interfere with our results, we repeated between group comparisons after
excluding data from participants taking metformin, and the results remained unchanged (Table S1).
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Table 1. Comparison of vitamin D levels, cardiovascular risk factors, hormones, and liver markers after vitamin D or placebo supplementation.
Vitamin D group (n = 18) Placebo group (n = 19) % Change
Parameter Baseline 3 months p-value a Baseline 3 months p-value a Vitamin D Placebo p-value b
25OHD (nmol/L) 25.6±11.4 90.4 ± 19.5 <0.001* 30.9 ± 11.1 47.6 ± 20.5 <0.001 * 319 ± 214 59.5 ± 56.7 <0.001 **
Weight (kg) 97.9 ± 31.3 98.2 ± 31.9 0.75 93.8 ± 22.3 94.3 ± 21.5 0.51 1.6(4.1) 0.7(3.7) 0.87
BMI (kg/m2) 35.4 ± 10.6 35.5 ± 10.8 0.76 33.8 ± 7.2 34.0 ± 7.0 0.44 1.7(4.1) 0.7(3.7) 0.92
SBP (mmHg) 117 ± 9.0 116 ± 14.6 0.68 121 ± 15.6 122 ± 12.5 0.75 −0.9 ± 7.8 1.1 ± 7.6 0.42
DBP (mmHg) 69.0 (12.5) 73.0 (18.8) 0.55 80.9 ± 10.7 80.6 ± 10.7 0.1 1.7 ± 11.8 -0.2 ± 6.9 0.55
hs-CRP (mg/L) 2.6 (7.9) 2.3 (6.3) 0.69 2.7 (8.1) 3.4 (8.5) 0.14 17.7 ± 67.0 15.6 ± 45.5 0.91
TC (mmol/L) 4.9 (1.0) 4.9 (1.1) 0.24 4.9 ± 0.8 4.9 ± 0.8 1.00 −2.2(19.9) 5.3(14.9) 0.22
LDL-C (mmol/L) 3.0 ± 0.7 3.1 ± 0.7 0.29 3.0 ± 0.7 2.9 ± 0.6 0.65 7.3(19.3) −3.3(26.9) 0.26
HDL-C (mmol/L) 1.4 ± 0.3 1.3 ± 0.4 0.88 1.2 (0.5) 1.1 (0.4) 0.11 0.0(17.4) 0.0(6.3) 1.0
TG (mmol/L) 1.2 (0.8) 1.1 (0.9) 0.46 1.1 (0.8) 1.1(1.0) 0.12 13.8(45.3) 5.9(71.3) 0.39
Fasting glucose (mmol/L) 4.7(0.5) 4.6(0.7) 0.30 4.8 ± 0.4 4.8 ± 0.5 0.76 3.0 ± 8.9 0.7 ± 7.6 0.55
Fasting insulin (µIU/mL) 14.2 (12.8) 12.3 (17.1) 0.50 11.7 ± 6.5 12.8 ± 8.0 0.39 11.2 ± 43.2 16.3 ± 45.0 0.73
HOMA-IR 2.9 (2.8) 2.5 (3.9) 0.44 2.1 (2.1) 2.2 (2.8) 0.31 −16.3 ± 52.5 19.3 ± 54.3 0.051
FAI 5.3 (5.8) 4.9 (5.5) 0.31 5.5 ± 3.1 5.9 ± 3.4 0.42 −3.1(48.3) 6.3(41.6) 0.26
Testosterone (nmol/L) 1.1 (0.9) 1.1 (0.8) 0.27 1.1 ± 0.4 1.2 ± 0.4 0.18 −0.6 ± 45.3 11.3 ± 27.3 0.34
SHBG (nmol/L) 24.0 (24.8) 24.5 (19.8) 0.72 19.0 (17.0) 20.0 (13.0) 0.57 1.0 ± 16.1 2.8 ± 17.9 0.74
ALT (IU/L) 27.0 ± 12.2 22.1 ± 11.5 0.042 * 24.9 ± 14.9 28.2 ± 14.4 0.039 * −16.7 ± 25.7 18.6 ± 28.6 0.001 **
HA (ng/mL) 18.5 ± 9.9 12.6 ± 6.7 0.019 * 12.4 (9.4) 12.9 (12.7) 0.84 −18.7 ± 48.0 9.4 ± 58.6 0.12
PIIINP (ng/mL) 7.5 ± 2.0 6.5 ± 2.0 0.78 6.6 (2.5) 6.5 (2.2) 0.66 −10.2 ± 31.2 4.6 ± 30.3 0.15
TIMP-1 (ng/mL) 156 (55.4) 154 (55.3) 0.45 164 ± 42 154 ± 44 0.19 −0.9(54.1) −8.3(24.3) 0.71
ELF Score 8.1 ± 0.5 7.6 ± 0.8 0.022 * 7.8 ± 0.6 7.7 ± 0.7 0.68 −5.9 ± 10.2 −0.6 ± 9.7 0.11
Data are presented as mean ± SD if normally distributed, or median (interquartile range) if not normally distributed. a indicates p-values for within groups comparisons; b indicates p-values
for between group comparisons. Bold data indicate statistical significant p-values; * p < 0.05, significant different compared to baseline within group, ** p < 0.05, significant difference
between groups. 25OHD: 25-hydroxyvitamin D; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: high sensitivity-C-reactive protein;
TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL: high density lipoprotein cholesterol; TG: triglycerides; FAI: free androgen index; SHBG: sex hormone binding globulin;
HOMA-IR: homeostatic model assessment of insulin resistance; ALT: alanine aminotransferase; HA: hyaluronic acid; PIIINP: amino-terminal propeptide of type III procollagen;
TIMP-1: tissue inhibitor of metallo-proteinases-1; ELF Score: enhanced liver fibrosis.
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4. Discussion
In this study, we demonstrate that compared to placebo, vitamin D supplementation resulted in
modest improvements in ALT and insulin resistance, whereas no further between-group differences
were seen in cardiovascular risk factors or hormones. Within group comparisons also showed
that supplementation with vitamin D (3200 IU/day) over a 3-month period resulted in significant
improvements in individual liver markers (ALT, HA,) and in the ELF score compared to baseline in
overweight and obese vitamin D deficient women with PCOS.
There is evidence to suggest that women with PCOS are more susceptible to NAFLD
than BMI-matched controls [3,4], and despite the reversibility of the disease, treatment options
are largely unexplored in this population. In the present vitamin D supplementation study, we
assessed liver fibrosis by HA, PIIINP, and TIMP-1, each of which reflect ongoing sinusoidal
fibrogenesis and fibrolysis in the liver, and their composite ELF score [21]. The ELF score
can accurately differentiate mild (<7.7), moderate (≥7.7 to <9.8), and severe fibrosis (≥ 9.8), and is
suggested to be a prognostic tool with good predictability of clinical outcomes [27,28]. In our
study, the treatment group had a reduction in ALT levels and went from a moderate to a mild
fibrosis category, as indicated by a significant drop in the ELF score post-intervention (within group
comparison). In contrast, ALT levels increased in the placebo group within the timeframe of
the study. The reason behind this increase in the placebo group is unclear, and may involve
a worsening metabolic profile due to the PCOS progression. Whereas there are no comparative
data from vitamin D supplementation studies on liver markers in PCOS, the positive changes
in markers of liver fibrosis in the present study are in accordance with relevant animal studies
demonstrating beneficial effects of vitamin D on liver histology [35,36], but also human studies in
patients with NAFLD [23–25,37]. For example, Papapostoli et al. demonstrated favorable alterations
in transient elastography (controlled attenuation parameter) after a 6-month vitamin D treatment
(20,000 IU per week) [23]. By using liver biopsy, Geier et al. also suggested a trend towards reduced
hepatic steatosis in patients with histologically determined NASH, treated with daily vitamin D
(2100 IU) for 48 weeks, although due to the limited number of specimens, these results did not reach
significance [25]. In agreement with our ALT results, in the same study, patients in the vitamin D group
had significantly reduced ALT levels after the end of the supplementation period compared to
placebo [25]. Similarly, Dasarathy et al., reported improvements in ALT levels only in responders
to vitamin D supplementation, defined as those whose vitamin D levels were >30 ng/ml following
supplementation with 2000IU vitamin D daily for 6 months [38]. Two other trials also showed greater
reductions in ALT levels in NAFLD patients who were randomized to a lifestyle modification program
plus vitamin D supplementation, compared to those who received the lifestyle modification programs
only [24,37].
Several potential mechanisms have been suggested by which vitamin D reduces the hepatic
steatosis and fibrosis in NAFLD patients [17,33]. The key process that leads to the development
of liver fibrosis in NAFLD patients is the activation of hepatic stellate cells, by fatty infiltration,
with subsequent excessive deposition of extracellular matrix and destruction of normal liver
architecture [21]. Recent studies have shown that hepatic stellate cells express vitamin D receptors,
which when activated, can inhibit hepatic stellate cells proliferation by suppressing fibrotic gene
expression [39]. These data are in accord with in-vitro studies on human cells [40] and animal
models, showing that vitamin D treatment inhibited fibrogenesis [41] and suppressed hepatic steatosis
and fibrosis by enhancing hepatic autophagy [42]. Other proposed mechanisms that also link vitamin D
with NAFLD include improvements in insulin sensitivity and reduction of inflammation [21,22].
Indeed, some clinical trials have shown that treatment with vitamin D improves parameters of insulin
sensitivity in patients with NAFLD [24], a finding consistent with the weak effect indicative of
a reduction in the HOMA-IR shown in the present study. At a molecular level, these effects may be
due to vitamin D-related enhancements in glucose transport in muscles, upregulation of the glucose
transporter type 4 (GLUT4) expression and translocation in cell surfaces, with subsequent glucose use
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by adipocytes [22]. Reduction of inflammation may also explain the effects of vitamin D on improving
NAFLD. For instance, artificial lighting in rats decreased the degree of inflammation and hepatic
apoptosis. In humans, some studies suggest reductions in markers of inflammation and oxidative
stress following vitamin D supplementation [43], although we, as well others [44,45], did not show
any vitamin D effects on hs-CRP.
With the exception of a weak effect indicating a reduction in HOMA-IR in
the supplementation group compared to the placebo group, vitamin D supplementation had
no significant effect on cardiovascular risk factors, including body weight, glucose and insulin
levels, and lipid profile. Vitamin D supplementation studies have reported positive [10–14] or no
changes in metabolic markers [16–20] in this population. In accordance with the HOMA-IR results in
our study, a recent meta-analysis of RCTs suggested that the HOMA-IR also declined significantly
when vitamin D was supplemented at doses lower than 4000 IU/day [11]. Conversely, Asemi et al.
explored the effects of 50,000 IU vitamin D per week over 8 weeks in PCOS and found no significant
differences in insulin resistance or blood lipids compared to placebo [20]. Similarly, Garg et al.
revealed no differences in measures of insulin resistance and sensitivity in PCOS women randomized
to either 120,000 IU of cholecalciferol monthly or placebo over 6 months (PCOS women in both groups
also received 1500 mg of metformin daily) [18]. We also showed no significant alterations in FAI,
testosterone, or SHBG in PCOS in response to vitamin D supplementation; these findings are consistent
with two recent meta-analyses on the vitamin D effects in PCOS, which revealed no change in
testosterone or SHBG levels [46,47]. Contrary to these findings, reductions in FAI and testosterone
and elevations in SHBG were seen in women with PCOS following daily supplementation with
a “high vitamin D dose” (4000 IU/day), but not a “lower dose” (1000 IU/day), over a 12-week period
in a RCT that was not included in these meta-analyses [15]. These findings underscore the current lack
of consensus on the effects of vitamin D in PCOS, which can be largely explained by the heterogeneity
in study designs, sample sizes, characteristics of vitamin D supplementation (i.e., monotherapy or
add-on therapy, duration, frequency and dosage), and baseline vitamin D status.
Our study is strengthened by our design (double blind, randomized, placebo-controlled trial),
the low dropout rate, and the high level of compliance with supplementation (99%). In addition,
to detect early liver fibrosis in our population we relied on the assessment of multiple markers of
liver fibrosis in blood samples and the subsequent estimation of the ELF score; this method is less
onerous than a liver biopsy, but evidence-based in characterizing NAFLD severity and predicting
NAFLD-related outcomes [28,29]. We should also acknowledge our study limitations. The inclusion
of an additional approach to quantify liver fibrosis (i.e., the “gold standard” liver biopsy or other
non-invasive method) would be useful in confirming our findings and would provide therapeutic
insights into liver injury in this understudied health aspect in PCOS. Our study population
was relatively healthy, without severe liver fibrosis or metabolic abnormalities; thus, our findings may
be less relevant for women with PCOS with progressed NAFLD or type 2 diabetes. Vitamin D levels
were raised in the supplementation group, but also, albeit to a less degree, in the placebo group,
due to seasonal variations. Nevertheless, at 3 months follow-up, mean vitamin D levels in
the supplementation group were well within the normal range, but mean vitamin D levels in
the placebo group remained within the insufficiency range. A stable dose of metformin, which has been
shown to improve biochemical and metabolic variables in NAFLD [48], was an inclusion criterion
in our study. It is, however, unlikely that metformin contributed to the reported vitamin D effects,
since there were more patients on stable doses of metformin in the placebo group (n = 8), rather than in
the vitamin D group (n = 3). The notion that metformin did not interfere with our results is further
supported by the absence of changes in the results of the between group comparison after excluding
the participants taking metformin in both groups.
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5. Conclusions
In conclusion, this study supports beneficial effects of vitamin D supplementation on markers
of liver injury and fibrosis, and modest improvements in insulin resistance in overweight and obese
vitamin D deficient women with PCOS. In contrast, other cardiovascular risk factors and hormones did
not change in response to the 3-month vitamin D supplementation. These results need confirmation
in future larger-scale trials with a longer supplementation period conducted in women with PCOS
at different NAFLD stages.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/1/188/
s1, Table S1: Between group comparisons of cardiovascular risk factors, hormones, and liver markers after
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and the placebo group (n = 8).
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